INNA STRESZ: Open Payments
NPI 1033847546 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,294 in 136 payments from 40 companies in 2025. Trend: 2023 $108 · 2024 $663 · 2025 $3,294
Food & beverage: $3,016Education: $278
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 18 | $346 |
| Incyte Corporation | 9 | $260 |
| SOBI, INC | 12 | $251 |
| Merck Sharp & Dohme LLC | 9 | $198 |
| Exelixis Inc. | 5 | $184 |
| Lilly USA, LLC | 11 | $156 |
| AstraZeneca Pharmaceuticals LP | 7 | $144 |
| BIOTRONIK NRO, Inc. | 1 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $120 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $114 |
Products named: RYBREVANT, KEYTRUDA, VERZENIO, Prospera, Doptelet, IMFINZI, JAKAFI, CABOMETYX.
Industry payments across NV — which companies pay providers there.
